Related references
Note: Only part of the references are listed.Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination
Stephen S. Whitehead et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)
Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study
Xavier Saez-Llorens et al.
LANCET INFECTIOUS DISEASES (2018)
A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice
Viswanathan Ramasamy et al.
PLOS NEGLECTED TROPICAL DISEASES (2018)
Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo
Rahul Shukla et al.
FRONTIERS IN MICROBIOLOGY (2018)
Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris Are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies
Niyati Khetarpal et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2017)
Major findings and recent advances in virus like particle (VLP)-based vaccines
Mona O. Mohsen et al.
SEMINARS IN IMMUNOLOGY (2017)
Immune correlates of protection for dengue: State of the art and research agenda
Leah C. Katzelnick et al.
VACCINE (2017)
In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination
Stephen S. Whitehead et al.
PLOS NEGLECTED TROPICAL DISEASES (2017)
DNA-immunisation with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and Yellow Fever virus infection
Jose L. Slon Campos et al.
PLOS ONE (2017)
Dengue vaccine-induced CD8+ T cell immunity confers protection in the context of enhancing, interfering maternal antibodies
Jian Hang Lam et al.
JCI INSIGHT (2017)
Immune correlates for dengue vaccine development
Anon Srikiatkhachorn et al.
EXPERT REVIEW OF VACCINES (2016)
Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site
Scott A. Smith et al.
JOURNAL OF VIROLOGY (2016)
Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies
Ankur Poddar et al.
BMC BIOTECHNOLOGY (2016)
Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort
Leah C. Katzelnick et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment
Neil M. Ferguson et al.
SCIENCE (2016)
Protective and immunological behavior of chimeric yellow fever dengue vaccine
Scott B. Halstead et al.
VACCINE (2016)
Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice
Satoru Watanabe et al.
JOURNAL OF VIROLOGY (2015)
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease
S. R. Hadinegoro et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America
Luis Villar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Generation and preclinical immunogenicity study of dengue type 2 virus-like particles derived from stably transfected mosquito cells
Amporn Suphatrakul et al.
VACCINE (2015)
Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies
Lav Tripathi et al.
FRONTIERS IN MICROBIOLOGY (2015)
Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial
Maria Rosario Capeding et al.
LANCET (2014)
Functional Analysis of Antibodies against Dengue Virus Type 4 Reveals Strain-Dependent Epitope Exposure That Impacts Neutralization and Protection
Soila Sukupolvi-Petty et al.
JOURNAL OF VIROLOGY (2013)
The global distribution and burden of dengue
Samir Bhatt et al.
NATURE (2013)
Pichia pastoris-Expressed Dengue 2 Envelope Forms Virus-Like Particles without Pre-Membrane Protein and Induces High Titer Neutralizing Antibodies
Shailendra Mani et al.
PLOS ONE (2013)
The Economic Burden of Dengue
Duane J. Gubler
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2012)
Evaluation of Extracellular Subviral Particles of Dengue Virus Type 2 and Japanese Encephalitis Virus Produced by Spodoptera frugiperda Cells for Use as Vaccine and Diagnostic Antigens
Miwa Kuwahara et al.
CLINICAL AND VACCINE IMMUNOLOGY (2010)
Dengue vaccines: state of the art
Sathyamangalam Swaminathan et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2010)
Optimization of conditions for secretion of dengue virus type 2 envelope domain III using Pichia pastoris
Gaurav Batra et al.
JOURNAL OF BIOSCIENCE AND BIOENGINEERING (2010)
Genotype-Specific Neutralization and Protection by Antibodies against Dengue Virus Type 3
James D. Brien et al.
JOURNAL OF VIROLOGY (2010)
Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans
Wanwisa Dejnirattisai et al.
SCIENCE (2010)
Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties
Wenquan Liu et al.
VIRUS GENES (2010)
Immature Dengue Virus: A Veiled Pathogen?
Izabela A. Rodenhuis-Zybert et al.
PLOS PATHOGENS (2010)
Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses
Wahala M. P. B. Wahala et al.
PLOS PATHOGENS (2010)
The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1
Bimmi Shrestha et al.
PLOS PATHOGENS (2010)
Efficient Assembly and Secretion of Recombinant Subviral Particles of the Four Dengue Serotypes Using Native prM and E Proteins
Pei-Gang Wang et al.
PLOS ONE (2009)
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes
Soila Sukupolvi-Petty et al.
JOURNAL OF VIROLOGY (2007)
Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization
Annette A. Kraus et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus
Gregory D. Gromowski et al.
VIROLOGY (2007)
Flow cytometry-based assay for titrating dengue virus
CR Lambeth et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2005)
High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli
S Jaiswal et al.
PROTEIN EXPRESSION AND PURIFICATION (2004)
A ligand-binding pocket in the dengue virus envelope glycoprotein
Y Modis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells
WD Crill et al.
JOURNAL OF VIROLOGY (2001)
Share Paper
